Improvements in survival due to advances in antiretroviral therapy (ART) have led to a shift in the age distribution of those receiving HIV care, with increasing numbers of women living with HIV (WLWHIV) reaching menopausal age. We present a narrative literature review of 26 studies exploring the menopause transition in WLWHIV, focusing on: (1) natural history (2) symptomatology and management, and (3) immunologic and virologic effects.
INTRODUCTION
In 2014, approximately 36.9 million people were living with HIV globally, of whom over half were women. (http://www.unaids.org, accessed 07 January 2016). Advancements in antiretroviral therapy (ART) have resulted in significant improvements in survival, such that people with wellcontrolled HIV may expect a near normal life expectancy.(1) Increasing coverage of ART has therefore led to a shift in the demographic profile of the HIV epidemic, reflected in increasing HIV prevalence rates among older people.(2) In 2014 nearly 25,100 people aged 50 and over attended clinical services for HIV-related care in the United Kingdom (UK), a four-fold increase since 2005 . Approximately 8700 women of potentially menopausal age (i.e. between 45 and 56 years) attended for HIV-related care in the UK in 2014 (Zheng Yin, Public Health England, personal communication, 26/02/16). Based on the observed age distribution of women attending for HIV care in the UK in 2013, a total of 10,000 women are likely to reach potentially menopausal age in the next ten years (Zheng Yin, Public Health England, personal communication, 25/02/2016) . (3) A consequence of living longer with HIV is the increased likelihood of developing age-related conditions. For women living with HIV (WLWHIV) entering their midlife, this includes transition through the menopause. In the shorter term, it is known that the menopause transition is frequently associated with a range of physical and psychological changes. Approximately 85% of women report symptoms such as hot flushes, sleep disturbance and mood changes,(4) with vasomotor symptoms lasting a median duration of 7.4 years.(5) Menopausal symptoms impact negatively upon women's quality of life, their role performance at work, and their relationships. (6, 7) Furthermore, the loss of the protective effects of estrogen brings an attendant risk of longer-term conditions such as dyslipidemia, osteoporosis and cardiovascular disease, which is likely to be of particular significance for WLWHIV as the risk of developing these conditions is elevated in the context of HIV infection. (8) Gonadal dysfunction is well-described in HIV-positive men, and ovarian dysfunction has been reported in WLWHIV. (9) The mechanisms for this remain unclear but may include: (i) direct effects of the virus itself, (ii) the effects of chronic inflammation on the neuroendocrine axis, (iii) effects of ART, and (iv) co-existing factors such as smoking, low body mass, or substance misuse. This may alter the natural history and/or symptomatology of the menopause in WLWHIV. Transitioning through the menopause in the context of chronic illness may present additional challenges in terms of ascertaining symptom etiology, with evidence to suggest that menopause-related symptoms in WLWHIV are under-recognized by healthcare providers. (10) We present a narrative review of literature on the menopause in WLWHIV. Although noting the growing body of literature on the effects of reproductive ageing on risk of bone disease in WLWHIV, we feel this merits a review of its own and is therefore outside the scope of this paper. Our specific objectives were to summarize data in WLWHIV on the following: (1) the natural history of the menopause, (2) symptomatology of the menopause transition and its management, and (3) the immunologic and virologic effects of the menopause transition.
METHODS

Data extraction
We undertook a comprehensive literature search in December 2015 using the following online databases: PubMed, Embase, CINAHL, and Web of Science. Our aim was to identify original research papers that explored menopause in WLWHIV. Search terms used to identify literature included: climacteric, menopaus*, pre-menopaus*, post-menopaus*, "pre menopaus*" and "post menopaus*", all in combination with HIV. We applied these search terms to abstracts and title in all databases, and restricted all searches to studies in human females only. There was no date restriction for any of the searches, and studies using any methodological approach were considered. Our initial literature search identified 399 documents, of which 162 were primarily focused on the menopause in WLWHIV. We reviewed these 162 documents, excluding review papers, non-English language publications, and studies that did not focus on any of our three key research questions. In addition, bibliographies of review papers were cross-referenced and we hand-searched available abstracts for the following conferences: British HIV Association (BHIVA), Conference for Retroviruses and Opportunistic Infections (CROI), and the International AIDS Society (IAS). The final number of studies included in this review is 26.
RESULTS
Natural history of the menopause in women living with HIV
The average age at natural menopause in the UK is 52 years.(11) Several cross-sectional studies in WLWHIV, almost all using self-reported menstrual pattern to categorize menopausal status, have reported a younger median age at menopause, ranging from 47.5 to 50 years (Table 1) . (12) (13) (14) (15) Two prospective studies, including one of very few to have been conducted in Europe, have reported similar findings. (16, 17) , suggesting that WLWHIV may experience menopause at an earlier age. However, this is not supported by the only two studies that included an HIV-negative comparison group as part of their design, neither of which found any statistically significant difference in age at menopause by HIV serostatus. (18, 19) One of these was an analysis of data from the Women's Interagency HIV Study (WIHS), a United States (US) prospective observational cohort of women both living with, and at risk of, HIV infection.(19) It is the largest study to date to compare age at menopause in HIV-positive and HIV-negative women, and the only one to use biological markers of ovarian function.
Authors from Brazil and from the UK have reported a relatively high prevalence of menopause before 45 years of age in WLWHIV. (17, 20) The study from the UK, a small retrospective case notes review, found that 14% of 123 HIV-positive women attending their clinic aged 50 or older had experienced cessation of menstruation when they were younger than 45; half of these women had experienced premature ovarian insufficiency (POI), that is menopause at 40 years or younger. (20) This is similar to the prevalence of POI in the general UK population, which is estimated to be 7.4%.(21) Other authors have reported higher rates of POI in HIV-positive women, including 12% in a French cohort (16) and 26% in a US study, which found that POI was significantly more common in WLWHIV compared to their HIV-negative counterparts. (18) Recognized risk factors for earlier menopause such as smoking and substance misuse have been reported in studies of menopause in WLWHIV. (16) (17) (18) Co-infection with HIV and hepatitis C has also been shown to be associated with earlier menopause. (17) However, data on the association between direct HIV-related factors and either menopausal status or age at menopause are conflicting. Some authors have found no association with CD4 Count, HIV viral load and the use of ART, (12, 14, 19) whereas lower CD4 count has been shown to be a risk factor by others. (16) (17) (18) Evidence for a link between immunosuppression and menopause is further strengthened by data suggesting that lower CD4 count is associated with anovulatory cycles (22) and decreased levels of anti-mullerian hormone (AMH), a marker of ovarian reserve. (23) Furthermore, deranged follicle-stimulating hormone (FSH) levels have been described both in HIV infection itself and with use of ART, which may affect the diagnostic value of FSH in this group of women. (24) 
Symptomatology and management of the menopause transition in women living with HIV
We identified 15 studies investigating symptomatology and management of the menopause in WLWHIV, the majority conducted in the US (Table 2 ). Boonyanurak at al., (12) in their study of HIV-positive women in Thailand, found that night sweats and loss of sexual desire were more prevalent in postmenopausal WLWHIV compared to those who were premenopausal. One study has found no association between HIV-status and menopausal symptoms (including vasomotor, genitourinary and psychological symptoms), (25) whereas increased symptoms have been reported by other authors. (15, (26) (27) (28) (29) Vasomotor symptoms are relatively well-investigated in WLWHIV. The reported prevalence of vasomotor symptoms in HIV-positive women ranges from 64-87%, (14, 15, 25, (28) (29) (30) which is not dissimilar to the rate reported in women without HIV.(4) Higher CD4 counts appear to be associated with increased symptoms in HIV-positive women. (13, 29) HIV-infection has been found to be associated with increased prevalence, frequency and severity of vasomotor symptoms.(15, 28) Looby et al. (27) followed 66 HIV-positive and HIV-negative perimenopausal women longitudinally over a 12-month period, observing an increased severity of vasomotor symptoms in WLWHIV that persisted over time. Analyses of data from both this study and from the WIHS cohort, demonstrate an association between severity and persistence of vasomotor symptoms, and elevated levels of depression in WLWHIV. (26, 31) Another analysis of WIHS data also found that vasomotor symptoms were associated with decreased scores in cognitive measures, however there was no difference by HIV serostatus. (32) The prevalence of psychological symptoms (including depression and anxiety) in WLWHIV during the menopause transition ranges from 38% to over 95%, (15, 25, 26, 29, 31) with the variation likely to be largely due to the use of different outcome measures and differences in populations. Although psychological symptoms such as depression are reported more frequently by women in the context of HIV regardless of menopausal status, both Ferreira at al. (15) and Looby et al. (26) report an association between HIV-infection and increased psychological symptoms around the time of the menopause even when adjusting for previous history of poor mental health. In contrast, an analysis of WIHS data on 1170 women found that although depression is more prevalent among perimenopausal women when compared to premenopausal women, that this is not related to HIV serostatus. (31) Genitourinary symptoms are common both peri-and postmenopausally. It is estimated that the prevalence these symptoms in WLWHIV is 48-73%, (14, 15, 25, 29) with Ferreira et al. (15) reporting an association with HIV-infection. Decreased sexual function has been reported in WLWHIV at all ages, and has been shown to decline postmenopausally in women regardless of HIV serostatus. (33) Only one study has investigated dyspareunia in midlife WLWHIV, describing a prevalence of 41% in WLWHIV aged 40-60 years, although this was not significantly different to the prevalence in the HIV-negative comparison group. (34) We found very few studies that sought to explore management of the menopause in WLWHIV, and none that assessed efficacy or safety of interventions. Small studies have revealed low rates of hormone replacement therapy (HRT) use among WLWHIV, with estimated usage ranging from 0-11%. (13, 14, 20, 30) This may be related to limited awareness of the menopause within this patient group.(30)
Immunologic and virologic effects of the menopause transition in women living with HIV
The immunomodulatory effects of estrogen is well-recognized,(35) making the effects of estrogen depletion on the natural history of HIV-infection of particular interest. We identified four studies that investigate this (Table 3) 
CONCLUSION
Despite the growing numbers of women living with HIV who are transitioning through the menopause, existing data is scanty and frequently contradictory. Much of the available data comes from the USA, where the populations of women affected by HIV differ from those in Europe and the UK, making comparisons across studies and data sets problematic. The influence of viral activity and immune suppression as evidenced by the HIV viral load and CD4 count respectively on ovarian function may be an important consideration on the timing of menopause, although uncertainty remains about the impact of HIV on age at menopause. As HIV and its treatments can predispose to a variety of metabolic complications, many of which are also associated with ageing, the implications of menopausal changes for women with HIV are significant. Data on best management strategies for HIV-positive menopausal women are lacking, Despite UK recommendations that HRT should be discussed and offered to menopausal women,(40) there appear to be low rates of use by women living with HIV, with the reasons underlying this unknown. Given the complexity of the lives of women living with HIV, understanding the additional impact of menopause on quality of life, and women's abilities to engage with health-sustaining behaviors including adherence to ART and retention in care, are important issues for future research. There is likely to be a significant burden of unmet health needs among menopausal women living with HIV making a better understanding of the impact and best practice approaches to management an important priority for future investigation.
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